A chart review was conducted to identify patients with HIT type II who had been treated with lepirudin at two large academic medical centers. The investigational review board of both institutions ...

This small study demonstrated a high incidence of antibody development possibly associated with the long-term exposure to lepirudin; however, no adverse effects were associated with antibody ...